Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial

BACKGROUND: Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the progression of atherosclerotic lesions. We aim to explore the relationship between OPG and the prognosis of coronary artery disease (CAD). METHODS: Plasma OPG concentrations were measured in 3,766 patients with sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Teng, Zhao, Jian, Yan, Yechao, Liu, Junying, Zang, Jie, Zhang, Yaqi, Ruan, Kun, Xu, Hong, He, Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300416/
https://www.ncbi.nlm.nih.gov/pubmed/37388640
http://dx.doi.org/10.3389/fcvm.2023.1178153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300416/
https://www.ncbi.nlm.nih.gov/pubmed/37388640
http://dx.doi.org/10.3389/fcvm.2023.1178153

Ejemplares similares